

## Note

### Synthesis and biological activity of 4'-oxathiazolidinyl benzopyrazoles

N P Shetgiri\*, A D Chitre, S V Kokitkar, S M Ghate,  
S S Patil & R C Kelaskar

Department of Chemistry, Institute of Science, 15, Madam Cama  
Road, Mumbai 400 032, India.

Received 7 December 2004; accepted (revised) 16 June 2005

New 3-methyl-1-[(2'-substituted phenyl-4'-oxothiazolidinyl)-3'-amidomethyl]-5,6-substituted-benzopyrazoles **3** and 3-methyl-1-[(2'-substituted-phenyl-5'-methyl-4'-oxothiazolidinyl)-3'-amidomethyl]-5,6-substituted-benzopyrazoles **4** are synthesized, characterized and evaluated for their antimicrobial and antitubercular activity.

**Keywords:** Benzopyrazoles, antimicrobial activity, antitubercular activity

**IPC:** Int.Cl.<sup>8</sup> C 07 D

In pharmacological studies of benzopyrazoles and their derivatives they have been shown to possess a variety of activities including antimicrobial and antiinflammatory<sup>1</sup>. 4-Oxathiazolidines and their 5-arylmethylene derivatives also possess a variety of therapeutic activities<sup>2-4</sup>. Therefore, it was thought to combine benzopyrazole and oxathiazolidine rings together in a molecular framework to see the additive effects of these rings towards the biological activities.

In this paper we report the synthesis of 3-methyl-1-[(2'-substituted phenyl-4'-oxothiazolidinyl)-3'-amidomethyl]-5,6-substituted-benzopyrazoles **3** and 3-methyl-1-[(2'-substituted-phenyl-5'-methyl-4'-oxothiazolidinyl)-3'-amidomethyl]-5,6-substituted-benzopyrazoles **4** (**Scheme I**). These new compounds are evaluated for their antimicrobial and antitubercular activity.

5,6-Substituted-3-methylbenzopyrazole-1-acetic acid hydrazides **1** were prepared from 5,6-substituted-3-methylbenzopyrazoles. The reaction of compound **1** and substituted benzaldehydes in methanol as solvent and a few drops of acetic acid as a catalyst under reflux, afforded 5,6-substituted-3-methyl-1-(substituted benzalhydrazinocarbonylmethyl)benzopyrazoles **2** in good yields. The reaction of **2** with thioglycolic acid and thiolactic acid in dry benzene and after a convenient work-up, gave the corresponding

compounds 3-methyl-1-[(2'-substituted-phenyl-4'-oxothiazolidinyl)-3'-amidomethyl]-5,6-substituted-benzopyrazoles **3** and 3-methyl-1-[(2'-substituted-phenyl-5'-methyl-4'-oxothiazolidinyl)-3'-amidomethyl]-5,6-substituted-benzopyrazoles **4**, respectively (**Scheme I, Table I**).

### Antimicrobial activity


The compounds were screened<sup>5-6</sup> for their antibacterial activity against pathogenic organisms *E.coli*, *P.aureus*, *S.aureus*, *S.typhi*, *B.subtilis* and antifungal activity against *C.albicans*, *A.niger* and *A.fumigatus* by single disc method at different concentrations. The compounds were also screened for their *in vitro* antitubercular<sup>7</sup> activity against *H<sub>37</sub>R<sub>V</sub>* strain of *Mycobacterium tuberculosis*. The screening results exhibited the minimum inhibitory concentration (MIC) against the microorganisms in the range 25-250 µg/mL and are given in **Table II**. A commercial antibacterial Ampicillin and antifungal Micanazole were used as standards for comparison.

### Experimental Section

Melting points were determined in open capillaries and are uncorrected. IR spectra were recorded in KBr on a Perkin-Elmer FTIR-1600 Spectrophotometer; <sup>1</sup>H and <sup>13</sup>C NMR spectra on Bruker AM X (500 MHz) spectrometer using TMS as an internal standard (chemical shifts in  $\delta$ , ppm); and mass spectra on a Jeol JMS-D300 spectrometer. TLC was run on silica gel-G plates and spots were located by iodine vapours and ultra violet lamp with frequency 560 and 252 nm. Satisfactory C, H, N results were obtained for all the compounds.

**Synthesis of 5,6-substituted-3-methyl-1-(substituted-benzalhydrazinocarbonylmethyl)benzopyrazoles 2. General procedure.** A solution of compound **1** (0.1 mole) in dry methanol (200 mL) and benzaldehyde (0.1 mole) was refluxed on a water-bath for 5-6 hr. The reaction mixture was cooled; separated solid was filtered, washed with cold methanol and recrystallized from ethanol; yield 70-80%. The characterization data of **2** are given in **Table I**.

**Synthesis of 3-methyl-1-[(2'-substituted-phenyl-4'-oxothiazolidinyl)-3'-amidomethyl]-5,6-substituted-**



Scheme I

Table I — Characterization data of compounds 2, 3 and 4

Compd	R	R'	R''	m.p.°C	Spectral data
<b>2a</b>	Cl	H	OCH <sub>3</sub>	120-21	<sup>1</sup> HNMR(CDCl <sub>3</sub> ): δ 2.5 (s, 3H, CH <sub>3</sub> ), 3.8 (s, 3H, OCH <sub>3</sub> ), 4.2 (s, 2H, CH <sub>2</sub> ), 6.9-7.8 (m, 7H, ArH), 8.4 (s, 1H, N=CH), 13.0 (s, 1H, NH). <sup>13</sup> C NMR: δ14.127(CH <sub>3</sub> ), 55.341(CH <sub>2</sub> ), 63.914(OCH <sub>3</sub> ), 108.6-132.7 (12 Ar-C), 159.1 & 159.9 (2×C=N), 168.7 (C=O carbons). MS (EI): M <sup>+</sup> 356.5 and M <sup>2+</sup> peak at 358.6.
<b>2b</b>	Cl	H	CH <sub>3</sub>	235-36	<sup>1</sup> HNMR (CDCl <sub>3</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.6 (s, 3H, CH <sub>3</sub> ), 4.2 (s, 2H, CH <sub>2</sub> ), 6.9-7.8 (m, 7H, ArH), 8.4 (s, 1H, N=CH), 13.0 (s, 1H, NH)
<b>2c</b>	Cl	H	H	154-55	<sup>1</sup> HNMR (CDCl <sub>3</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 4.2 (s, 2H, CH <sub>2</sub> ), 6.7-7.1 (m, 8H, ArH), 8.2 (s, 1H, N=CH), 13.1 (s, 1H, NH)
<b>2d</b>	H	H	OCH <sub>3</sub>	220-22	<sup>1</sup> HNMR (DMSO- <i>d</i> <sub>6</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 3.7 (s, 3H, OCH <sub>3</sub> ), 4.2 (s, 2H, CH <sub>2</sub> ), 6.8-7.9 (m, 8H, ArH), 8.7 (s, 1H, N=CH), 12.8 (s, 1H, NH).
<b>2e</b>	H	H	CH <sub>3</sub>	110-11	<sup>1</sup> HNMR (CDCl <sub>3</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.3 (s, 3H, CH <sub>3</sub> ), 4.2 (s, 2H, CH <sub>2</sub> ), 6.7-7.6 (m, 8H, ArH), 8.0 (s, 1H, N=CH), 13.2 (s, 1H, NH).
<b>2f</b>	H	H	H	180-81	<sup>1</sup> HNMR (CDCl <sub>3</sub> ): δ 2.6 (s, 3H, CH <sub>3</sub> ), 4.1 (s, 2H, CH <sub>2</sub> ), 6.7-7.8 (m, 9H, ArH), 8.7 (s, 1H, N=CH), 13.5 (s, 1H, NH).
<b>2g</b>	Cl	CH <sub>3</sub>	OCH <sub>3</sub>	80	
<b>2h</b>	Cl	CH <sub>3</sub>	CH <sub>3</sub>	178-79	
<b>2i</b>	Cl	CH <sub>3</sub>	H	280-81	<sup>1</sup> HNMR (DMSO- <i>d</i> <sub>6</sub> ): δ 2.1 (s, 3H, CH <sub>3</sub> ), 2.4 (s, 3H, CH <sub>3</sub> ), 4.3 (s, 2H, CH <sub>2</sub> ), 6.9-7.8 (m, 8H, ArH), 8.7 (s, 1H, N=CH), 13.3 (s, 1H, NH).
<b>3a</b>	Cl	H	OCH <sub>3</sub>	189-90	<sup>1</sup> HNMR (CDCl <sub>3</sub> ): δ 2.5 (s, 3H, CH <sub>3</sub> ), 3.9 (s, 3H, OCH <sub>3</sub> ), 4.2 (s, 2H, CH <sub>2</sub> ), 5.0 (s, 2H, CH <sub>2</sub> ), 6.9-7.3 (m, 8H, ArH), 13.0 (s, 1H, NH). <sup>13</sup> C NMR: δ15.3 (CH <sub>3</sub> ), 55.8 (CH <sub>2</sub> ), 63.8 (OCH <sub>3</sub> ), 79.8 (CH <sub>2</sub> ), 118.7-131.8 (13 Ar-C), 159.5 (C=N), 167.9 and 174.0 (2×C=O).
<b>3b</b>	Cl	H	CH <sub>3</sub>	210-12	<sup>1</sup> HNMR (CDCl <sub>3</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.4 (s, 3H, CH <sub>3</sub> ), 4.1 (s, 2H, CH <sub>2</sub> ), 5.1 (s, 2H, CH <sub>2</sub> ), 6.8-7.4 (m, 7H, ArH), 13.2 (s, 1H, NH). MS (EI): M <sup>+</sup> peak at 414.8 and M <sup>2+</sup> peak at 416.9.

— Contd

**Table I** — Characterization data of compounds **2**, **3** and **4**—*Contd*

Compd	R	R'	R''	m.p.°C	Spectral data
<b>3c</b>	Cl	H	H	250-51	
<b>3d</b>	H	H	OCH <sub>3</sub>	156-57	<sup>1</sup> HNMR (DMSO- <i>d</i> <sub>6</sub> ): δ 2.4 (s, 3H, CH <sub>3</sub> ), 3.7 (s, 3H, OCH <sub>3</sub> ), 4.1 (s, 2H, CH <sub>2</sub> ), 5.1 (s, 2H, CH <sub>2</sub> ), 6.7-7.8 (m, 8H, ArH), 12.9 (s, 1H, NH). MS (EI): M <sup>+</sup> ion peak at m/z 396
<b>3e</b>	H	H	CH <sub>3</sub>	251-52	<sup>1</sup> HNMR (CDCl <sub>3</sub> ): δ 2.6 (s, 3H, CH <sub>3</sub> ), 2.4 (s, 3H, CH <sub>3</sub> ), 4.2 (s, 2H, CH <sub>2</sub> ), 5.1 (s, 2H, CH <sub>2</sub> ), 6.7-7.5 (m, 8H, ArH), 12.9 (s, 1H, NH)
<b>3f</b>	H	H	H	123-24	<sup>1</sup> HNMR (CDCl <sub>3</sub> ): δ 2.4 (s, 3H, CH <sub>3</sub> ), 4.1 (s, 2H, CH <sub>2</sub> ), 5.2 (s, 2H, CH <sub>2</sub> ), 6.6 - 7.7 (m, 8H, ArH), 12.8 (s, 1H, NH).
<b>3g</b>	Cl	CH <sub>3</sub>	OCH <sub>3</sub>	174-75	<sup>1</sup> HNMR (DMSO- <i>d</i> <sub>6</sub> ): δ 2.5 (s, 3H, CH <sub>3</sub> ), 3.7 (s, 3H, OCH <sub>3</sub> ), 4.1 (s, 2H, CH <sub>2</sub> ), 5.1 (s, 2H, CH <sub>2</sub> ), 6.6-7.7 (m, 7H, ArH), 12.9 (s, 1H, NH).
<b>3h</b>	Cl	CH <sub>3</sub>	CH <sub>3</sub>	190-92	<sup>1</sup> HNMR (CDCl <sub>3</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.3 (s, 3H, CH <sub>3</sub> ), 2.5 (s, 3H, CH <sub>3</sub> ), 4.3 (s, 2H, CH <sub>2</sub> ), 5.1 (s, 2H, CH <sub>2</sub> ), 6.7-7.5 (m, 7H, ArH), 13.2 (s, 1H, NH).
<b>3i</b>	Cl	CH <sub>3</sub>	H	210-12	<sup>1</sup> HNMR (DMSO- <i>d</i> <sub>6</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.3 (s, 3H, CH <sub>3</sub> ), 4.2 (s, 2H, CH <sub>2</sub> ), 5.1 (s, 2H, CH <sub>2</sub> ), 6.7-7.5 (m, 7H, ArH), 13.5 (s, 1H, NH).
<b>4a</b>	Cl	H	OCH <sub>3</sub>	262-63	<sup>1</sup> HNMR (CDCl <sub>3</sub> ): δ 2.5 (s, 3H, CH <sub>3</sub> ), 2.5 (s, 3H, CH <sub>3</sub> ), 3.9 (s, 3H, OCH <sub>3</sub> ), 4.2 (s, 2H, CH <sub>2</sub> ), 5.0 (s, 1H, CH), 5.7 (s, 1H, CH), 6.8-7.8 (m, 8H, 1H & 7ArH), 12.9 (s, 1H, NH). <sup>13</sup> C NMR: 14.1 and 17.3 (2 -CH <sub>3</sub> ), 55.3 (CH <sub>2</sub> ), 64.0 (OCH <sub>3</sub> ), 83.570(tetrahedral carbon), 92.1 (ring tetrahedral carbon), 119.1 -133.4 (13 Ar-C), 157.2 (C=N), 168.7 and 173.8 (2 × C=O carbons).
<b>4b</b>	Cl	H	CH <sub>3</sub>	214-15	<sup>1</sup> HNMR (DMSO- <i>d</i> <sub>6</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.6 (s, 3H, CH <sub>3</sub> ), 2.7 (s, 3H, CH <sub>3</sub> ), 4.3 (s, 2H, CH <sub>2</sub> ), 5.2 (s, 1H, CH), 5.8 (s, 1H, CH), 6.8-7.7 (m, 7H, ArH), 13.0 (s, 1H, NH). <sup>13</sup> C NMR: δ14.6, 16.9 & 17.8 (3 -CH <sub>3</sub> ), 57.6 (CH <sub>2</sub> ), 82.8 (tetrahedral carbon), 92.7 (ring tetrahedral carbon), 221.0-131.8 (12 Ar-C), 157.7 (C=N), 168.9 and 174.7 (2×C=O carbons).
<b>4c</b>	Cl	H	H	181-82	<sup>1</sup> HNMR (DMSO- <i>d</i> <sub>6</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.6 (s, 3H, CH <sub>3</sub> ), 4.3 (s, 2H, CH <sub>2</sub> ), 5.2 (s, 1H, CH), 5.8 (s, 1H, CH), 6.8-7.8 (m, 7H, ArH), 13.0 (s, 1H, NH).
<b>4d</b>	H	H	OCH <sub>3</sub>	215-16	<sup>1</sup> H NMR (CDCl <sub>3</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.6 (s, 3H, CH <sub>3</sub> ), 3.7 (s, 3H, OCH <sub>3</sub> ), 4.3 (s, 2H, CH <sub>2</sub> ), 5.2 (s, 1H, CH), 5.8 (s, 1H, CH), 6.8-7.7(m, 8H, ArH), 13.0 (s, 1H, NH).
<b>4e</b>	H	H	CH <sub>3</sub>	148-50	<sup>1</sup> H NMR: δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.6 (s, 3H, CH <sub>3</sub> ), 2.7 (s, 3H, CH <sub>3</sub> ), 4.3 (s, 2H, CH <sub>2</sub> ), 5.2 (s, 1H, CH), 5.8 (s, 1H, CH), 6.6-7.8(m, 8H, ArH), 13.0 (s, 1H, NH).
<b>4f</b>	H	H	H	287-88	
<b>4g</b>	Cl	CH <sub>3</sub>	OCH <sub>3</sub>	193-95	<sup>1</sup> H NMR (DMSO- <i>d</i> <sub>6</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.6 (s, 3H, CH <sub>3</sub> ), 2.7 (s, 3H, CH <sub>3</sub> ), 3.7 (s, 3H, OCH <sub>3</sub> ), 4.3 (s, 2H, CH <sub>2</sub> ), 5.2 (s, 1H, CH), 5.8 (s, 1H, CH), 6.8-7.7 (m, 7H, ArH), 13.0 (s, 1H, NH).
<b>4h</b>	Cl	CH <sub>3</sub>	CH <sub>3</sub>	204-05	<sup>1</sup> H NMR (CDCl <sub>3</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.6 (s, 3H, CH <sub>3</sub> ), 2.9 (s, 3H, CH <sub>3</sub> ), 4.3 (s, 2H, CH <sub>2</sub> ), 5.2 (s, 1H, CH), 5.8 (s, 1H, CH), 6.5 - 7.8 (m, 7H, ArH), 13.0 (s, 1H, NH).
<b>4i</b>	Cl	CH <sub>3</sub>	H	106-07	<sup>1</sup> H NMR (DMSO- <i>d</i> <sub>6</sub> ): δ 2.2 (s, 3H, CH <sub>3</sub> ), 2.6 (s, 3H, CH <sub>3</sub> ), 4.4 (s, 2H, CH <sub>2</sub> ), 5.6 (s, 1H, CH), 5.9 (s, 1H, CH), 6.8 - 7.8 (m, 7H, ArH), 12.8 (s, 1H, NH).

**Table II** — Antimicrobial activities of compounds **2a-i**, **3a-i** and **4a-i**

Compd	Antibacterial activity					Antifungal activity			Antitubercular activity <i>H</i> <sub>37</sub> <i>R</i> <sub>V</sub>
	<i>E.coli</i>	<i>P. aureus</i>	<i>S. aureus</i>	<i>S.typhi</i>	<i>B. subtilis</i>	<i>C. albicans</i>	<i>A. niger</i>	<i>A. fumigatus</i>	
<b>2a</b>	+++	-	++	-	-	+	++	-	-
<b>2b</b>	++	+	++	-	+++	+	+	+	-
<b>2c</b>	++	++	-	-	++	-	-	-	-
<b>2d</b>	++	++	-	+++	+	-	-	-	-
<b>2e</b>	-	+	-	++	++	++	+	++	-
<b>2f</b>	-	+	++	+++	+	+	+	+++	-
<b>2g</b>	-	+	+	+	+	++	++	-	-
<b>2h</b>	-	++	++	+	++	++	++	+	-
<b>2i</b>	+	++	++	++	++	++	+++	-	-

—*Contd*

**Table II** — Antimicrobial activities of compounds **2a-i**, **3a-i** and **4a-I**—*Contd*

Compd	Antibacterial activity					Antifungal activity			Antitubercular activity <i>H<sub>37</sub>R<sub>V</sub></i>
	<i>E. coli</i>	<i>P. aureus</i>	<i>S. aureus</i>	<i>S. typhi</i>	<i>B. subtilis</i>	<i>C. albicans</i>	<i>A. niger</i>	<i>A. fumigatus</i>	
<b>3a</b>	+	+	-	++	-	+	+++	++	-+
<b>3b</b>	++	-	-	+	-	++	-	-	++
<b>3c</b>	++	+	+	++	-	++	+++	-	+
<b>3d</b>	++++	-	+	+	-	+++	+	-	+
<b>3e</b>	+	-	++	+	++	-	+	++	++
<b>3f</b>	+	++	-	-	+	++	-	++	++
<b>3g</b>	+	-	-	++	+	++	-	+	++
<b>3h</b>	-	-	+	++	+	++	-	+	+
<b>3i</b>	-	+	+	++	++	+	-	++	+
<b>4a</b>	-	++	+++	++	++	+	++	++++	++
<b>4b</b>	++	++	++	+	+++	-	++	+++	++
<b>4c</b>	++	++	-	-	+	-	++	++	++
<b>4d</b>	++	++	+	-	+	-	+	-	++
<b>4e</b>	+	+++	-	-	+	+	+	-	+
<b>4f</b>	+++	+++	-	+	-	+	+	-	+
<b>4g</b>	+	+	+	-	-	++	++	+	-
<b>4h</b>	+	+	++	-	-	+	++	+	-
<b>4i</b>	-	+	++	-	-	-	+	+	-

Where; ++++ 50 µg/mL, +++ 100 µg/mL, ++ 200 µg/mL, + 250 µg/mL

**benzopyrazoles 3. General procedure.** A mixture of **2** (0.01 mole) in dry benzene (40 mL) and thioglycolic acid (0.012 mole) was refluxed on a water-bath for 8-9 hr. The excess solvent was removed under vacuum and residue was poured into ice cold water and then neutralized with sodium bicarbonate solution. Solid separated was filtered, dried and recrystallized from aqueous ethanol, yield 65-70%. The characterization data of **3** are given in **Table I**.

**Synthesis of 3-methyl-1-[(2'-substituted-phenyl-5'-methyl-4'-oxothiazolidinyl)-3'-amidomethyl]-5,6-substituted-benzopyrazoles 4. General procedure.** A mixture of **2** (0.01 mole) in dry benzene (40 mL) and thiolic acid (0.012 mole) was refluxed on a water-bath for 8-9 hr. The excess solvent was removed under vacuum and residue was poured into ice cold water and then neutralized with sodium

bicarbonate solution. Solid separated was filtered, dried and recrystallized in aqueous ethanol, yield 65-72%. The characterization data of **4** are given in **Table I**.

## References

- 1 Amir Mohd, Dhar Nirmal & Tiwari S K, *Indian J Chem*, **36B**, **1997**, 96.
- 2 Mousseron H J, *U S Pat*, **3**, 704 296, **1942**; *Chem Abstr*, **1973**, 78.
- 3 Dimri A K & Parmar S S, *J Heterocycl Chem*, **15**, **1978**, 335.
- 4 Esablishments Clin-Byla, *French Pat*, **1,604,530**, **1972**.
- 5 Joan Stokes E, *Clinical bacteriology*, 4<sup>th</sup> edn, (Academic Press, London & New York), **1975**, 226.
- 6 Baur A W, Sherries W W & Jurk J C K, *Am J Clin Path*, **45**, **1966**, 493.
- 7 Koneman E V, Jonda W M, Allen W D, Sommers H M, Dowell V R & Winn W C, *Color Atlas and text book of Diagnostic Microbiology*, 3<sup>rd</sup> edn, (Butterworth and Co. Publisher Ltd.), **1988**, 487.